Penn Spinout Vittoria Biotherapeutics Emerges from Stealth Mode with $10M Seed Round

Jun 07, 2022

A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.

Vittoria Biotherapeutics’ mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies to create new therapies that address unmet clinical needs. The technology the company is attempting to commercialize was developed by Dr. Marco Ruella, a hematologist from Italy who came to the United States 10 years ago to study under Penn CAR T-cell pioneers Dr. Carl June and Saar Gill.

Read more >